Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heated chemo during surgery may boost ovarian cancer survival

NCT ID NCT03772028

Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to see if the extra treatment improves overall survival and delays cancer return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 538 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * candidate for primary CRS * histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer Exclusion Criteria: * history of previous malignancies within 5 years prior to inclusion * FIGO stage IV disease * complete primary cytoreduction is impossible * prior treatment for the current malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Alice Bjoernlund-Larsen

    Uppsala, Sweden

  • Amsterdam UMC

    Amsterdam, Netherlands

  • Antoni van leeuwenhoek

    Amsterdam, North Holland, 1066CX, Netherlands

  • CHRU Strasbourg

    Strasbourg, France

  • CHU Lille

    Lille, France

  • CHU Lyon

    Lyon, France

  • CHU de Besancon

    Besançon, France

  • Catharina Hospital

    Eindhoven, Netherlands

  • Centre Leon Berard, Lyon

    Lyon, France

  • City of Hope

    Duarte, California, 91010, United States

  • Erasmus MC

    Rotterdam, Netherlands

  • Fondazione Policlinico A Gemelli IRCCS

    Roma, Italy

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie Paris

    Paris, France

  • Institut de Cancerologie de l'Ouest, ICO Nantes)

    Nantes, France

  • Institut du Cancer Montpellier

    Montpellier, France

  • Leiden University Medical Center (LUMC)

    Leiden, Netherlands

  • MSKCC New York

    New York, New York, 10065, United States

  • Maastricht UMC+

    Maastricht, Netherlands

  • Mater Misericordiae University Hospital, Dublin

    Dublin, Ireland

  • Medisch Spectrum Twente

    Enschede, Netherlands

  • Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse)

    Toulouse, France

  • Policlinico Sant'Orsola, Bologna

    Bologna, Italy

  • Radboud MC

    Nijmegen, Netherlands

  • Rigshospitalet Copenhagen

    Copenhagen, Denmark

  • UMCG

    Groningen, Netherlands

  • UMCU

    Utrecht, Netherlands

  • o Institut Bergonié, Bordeaux

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.